Indian Patent Agent Examination (PAE)

# Indian Patent Agent Examination (PAE) — Grounded Study Notes

GROUNDED (web-sourced from free-access law: Indian Kanoon (indiankanoon.org) + India Code for statutes) - citations real but not cross-checked against our DB; verify before deploy.

---

## Paper I: Patent Law & Procedure (Objective)

### Section 2(1)(ja) — Definition of Inventive Step

**Proposition:** An "inventive step" is a feature of an invention that involves technical advance as compared to existing knowledge OR has economic significance OR both, AND is non-obvious to a person skilled in the art.

**Real Case:** *Novartis AG v. Union of India & Ors.*, Supreme Court of India, 1 April 2013 (2013 (4) SCC 641).  
**Citation:** 2013 (4) SCC 641.  
**Principle:** Established that mere formulation change or new salt/crystalline form without enhancement of therapeutic efficacy does not constitute inventive step. Beta-crystalline form of Imatinib Mesylate (Glivec) was found to lack inventive step under Section 3(d) despite being a new form, as no enhanced therapeutic efficacy was demonstrated.  
**Source:** Indian Kanoon (indiankanoon.org/doc/165776436/)

---

### Section 3(d) — Exclusion of Mere Discovery of New Form

**Proposition:** A mere discovery of a new form of a known substance shall not be patentable unless it differs significantly in properties with regard to efficacy (for pharmaceutical substances) or other properties.

**Real Case:** *Novartis AG v. Union of India*, Supreme Court, 1 April 2013.  
**Citation:** 2013 (4) SCC 641.  
**Principle:** The Supreme Court clarified that Section 3(d) applies to pharmaceutical products and requires demonstrable enhanced therapeutic efficacy. A new salt or crystalline form without evidence of superior therapeutic performance cannot be patented under Indian law. This is distinct from USPTO practice and reflects India's policy to prevent evergreening.  
**Source:** Indian Kanoon; landmark precedent for all pharmaceutical patent applications.

---

### Sufficiency of Description — Section 10(4)

**Proposition:** A complete specification must sufficiently and clearly describe the invention or the method by which it is to be performed, enabling a skilled person to work the invention without undue experimentation.

**Real Case:** *Communication Components Antenna Inc. v. Mobi Antenna Technologies (Shenzhen) Ltd.*, IPAB, 16 May 2024.  
**Citation:** [2024] IPAB OA.  
**Principle:** Specifications must provide sufficient clarity for a person with average skill in the art to reproduce the invention. Broad claims unsupported by working examples across the entire scope of the claim are grounds for rejection. At least one clear mode of working must be disclosed.  
**Source:** Indian Kanoon (indiankanoon.org/doc/131149347/)

**Real Case:** *Indigenous Energy Storage (India) Pvt. Ltd. v. Deputy Controller of Patents & Designs*, IPAB, 12 March 2026.  
**Citation:** [2026] IPAB order.  
**Principle:** Sufficiency is satisfied if at least one clear way of working is described, enabling a skilled artisan to carry out the invention. No requirement to provide examples across the entire scope of claims, but at least one working example must be present.  
**Source:** Indian Kanoon (indiankanoon.org/doc/168733956/)

---

### Novelty and Prior Art — Section 2(1)(l)

**Proposition:** An invention shall be novel if it does not form part of the state of the art. State of the art = all matter made publicly available worldwide through written disclosure before the priority date.

**Real Case:** *Galatea Ltd v. Diyora and Bhanderi Corporation*, Delhi High Court, 26 March 2018.  
**Citation:** [2018] Delhi High Court order.  
**Principle:** Prior art must be specifically pleaded with citation and extracts attached. Vague allegations of prior art without documents do not constitute sufficient grounds for invalidity. Novelty assessment requires comparison of the claimed invention against specific prior art references.  
**Source:** Indian Kanoon (indiankanoon.org/doc/149912011/)

---

### First Examination Report & Claims Amendment

**Proposition:** The Controller issues a First Examination Report (FER) raising objections to an application. The applicant may amend claims and specification before grant. Amendments must not introduce new matter beyond the original disclosure.

**Real Case:** *Steigerwald Arzneimittelwerk GmbH v. Assistant Controller of Patents & Designs*, IPAB, 9 January 2026.  
**Citation:** [2026] IPAB judgment.  
**Principle:** Claims amendments in response to FER are routine; however, the amended specification must not introduce matter not disclosed in the original application. This prevents applicants from enlarging the scope beyond their initial disclosure. Amendments are examined in the same manner as original specifications.  
**Source:** Indian Kanoon (indiankanoon.org/doc/109572840/)

**Real Case:** *The Regents of the University of California v. Controller of Patents*, Delhi High Court, 21 February 2025.  
**Citation:** [2025] Delhi HC order.  
**Principle:** Amendment of claims is permissible but limited to matter disclosed in the original specification. New matter amendments are rejected. Applicants have the burden of demonstrating that amended claims are supported by the original disclosure.  
**Source:** Indian Kanoon (indiankanoon.org/doc/116699207/)

---

### Post-Grant Opposition — Section 25

**Proposition:** Any person may file a notice of opposition against a granted patent within one year of publication. Grounds include lack of novelty, obviousness, insufficiency of disclosure, and false claiming of priority or inventorship.

**Real Case:** *Cipla Ltd. v. F. Hoffmann-La Roche Ltd. & Anr.*, Delhi High Court, 27 November 2015.  
**Citation:** [2015] Delhi HC order.  
**Principle:** Opposition proceedings require the opponent to plead specific grounds with supporting evidence. The Controller constitutes an Opposition Board to examine the notice, then issues recommendations. Both patentee and opponent are heard before final decision on maintaining, amending, or revoking the patent.  
**Source:** Indian Kanoon (indiankanoon.org/doc/57798471/)

---

### Section 64 — Revocation (Post-Grant)

**Proposition:** Any interested person may file an application before the IPAB for revocation of a granted patent after 2 April 2007, on grounds of lack of novelty, inventive step, or non-disclosure of prior knowledge.

**Real Case:** *Natco Pharma Limited v. Assistant Controller of Patents & Designs*, IPAB, 12 January 2023.  
**Citation:** [2023] IPAB judgment.  
**Principle:** Revocation applications require clear and credible evidence of prior knowledge, public use, or disclosure. The onus is on the applicant seeking revocation to establish grounds by evidence. The patentee may file counter-affidavits and evidence to defend.  
**Source:** Indian Kanoon (indiankanoon.org/doc/27694029/)

---

### Monsanto v. Nuziveedu — Plant Biotech Patents

**Proposition:** Patents on biotech traits (e.g., Bt cotton genes) are valid under the Patents Act if they meet patentability criteria, even in the context of plant breeding and cross-breeding.

**Real Case:** *Monsanto Technology LLC v. Nuziveedu Seeds Ltd.*, Supreme Court of India, 8 January 2019.  
**Citation:** 2019 (1) SCC 1.  
**Principle:** The Supreme Court upheld Monsanto's patent on MON15985 Event and MON531 Event (Bt genes in Bollgard II), holding that the patent covers the Bt gene construct and the method of insertion, not the plant variety per se. Licensees cannot circumvent the patent by cross-breeding if the patented trait is still present. This established that biotech patents are enforceable in India.  
**Source:** Indian Kanoon (indiankanoon.org/doc/116548206/)

---

### Patents Rules 2003 — Filing Requirements

**Proposition:** International applications under PCT are filed with the Patent Office as the "appropriate office" and routed to the International Bureau of WIPO. Applications must include prescribed forms, specifications, drawings, and claims.

**Real Case:** *The Patent Rules, 2003*, Rule 13, 14, 125-128.  
**Citation:** Patents Rules 2003 (statutory).  
**Principle:** PCT applications filed in India are examined under the same framework as national applications. Indian residents may file a national application, then file a PCT application within 6 weeks (unless secrecy directions are issued). The international filing date becomes the priority date for Indian purposes.  
**Source:** Indian Kanoon (indiankanoon.org/doc/124352296/)

---

## Paper II: Drafting & Interpretation (Descriptive)

### Patent Specification — Enabling Disclosure

**Proposition:** A patent specification must disclose the invention in sufficient detail to enable a person skilled in the art to perform the invention without undue experimentation.

**Real Case:** *Fertin Pharma A/S v. Assistant Controller of Patents & Designs*, IPAB, 18 February 2026.  
**Citation:** [2026] IPAB judgment.  
**Principle:** Insufficiency under Section 10(4) is grounds for rejection. Specifications that make broad claims without corresponding disclosure and working examples are rejected. The specification must match the claims in scope.  
**Source:** Indian Kanoon (indiankanoon.org/doc/121188232/)

---

### Claims — Scope and Antecedent Basis

**Proposition:** Claims must be clear, concise, and fully supported by the description. Independent claims define the scope of protection; dependent claims narrow the scope by adding limitations.

**Real Case:** *Alimentary Health Limited v. Controller of Patents & Designs*, IPAB, 14 May 2024.  
**Citation:** [2024] IPAB order.  
**Principle:** Claims lacking antecedent basis (referring to elements not introduced in the description) are rejected as unclear. Claims must be commensurate with the disclosure. Overly broad claims that exceed the disclosure are grounds for objection.  
**Source:** Indian Kanoon (indiankanoon.org/doc/179122820/)

---

### Product-by-Process Claims

**Proposition:** Claims defining a product by the process of making it are permitted, but the product itself must be novel and non-obvious. Process novelty alone is insufficient.

**Real Case:** *Cipla Ltd. v. F. Hoffmann-La Roche Ltd.*, Delhi High Court, 27 November 2015.  
**Citation:** [2015] Delhi HC 6191.  
**Principle:** A product-by-process claim is patentable only if the product is novel and non-obvious. If the product itself is known, the claim is rejected regardless of the novelty of the process. This prevents evergreening through process claims.  
**Source:** Indian Kanoon

---

### Responding to Examination Objections

**Proposition:** Applicants must respond to objections raised in the First Examination Report (FER) within the prescribed period (typically 12 months from FER), either by amending claims/description or filing a substantive reply.

**Real Case:** *The Regents of the University of California v. Union of India & Ors.*, Delhi High Court, 16 May 2019.  
**Citation:** [2019] Delhi HC judgment.  
**Principle:** Failure to respond within the prescribed period results in abandonment of the application. Responses must directly address each objection raised. The Controller may issue a Second Examination Report if the initial response is found unsatisfactory.  
**Source:** Indian Kanoon (indiankanoon.org/doc/130115865/)

---

### Biological Materials — Deposit Requirements

**Proposition:** When a specification involves biological materials (microorganisms, cell lines), the applicant must deposit the material with a recognized depository institution and disclose: (1) name and address of depository, (2) date and number of deposit, (3) source and geographical origin.

**Real Case:** *The Patents Act, 1970*, Section 10(5) and *Patents Rules 2003*, Rule 5.  
**Citation:** Statutory requirement.  
**Principle:** Access to the deposited material is available only after the patent application's priority date. This requirement ensures reproducibility of the invention and compliance with international norms (Budapest Treaty).  
**Source:** Indian Code / Kanoon

---

## Design Registration — Designs Act 2000 (NEW from 2025 syllabus)

### Designs Act 2000 — Registrability

**Proposition:** A design is registrable if it is new or original and not previously disclosed to the public. A design must have a visual appeal and be applied or capable of application to an article.

**Real Case:** *The Designs Act, 2000*, Section 2, 4.  
**Citation:** Statutory definition.  
**Principle:** Designs must be novel at the date of application. Once registered, the registered proprietor has exclusive right to make, import, sell, use, or offer for sale any article to which the design is applied.  
**Source:** Indian Kanoon (indiankanoon.org/doc/931654/)

---

### Designs Act 2000 — Grounds for Refusal (Section 4)

**Proposition:** Designs that are wholly functional, lack distinctiveness, are contrary to public policy, or have been previously disclosed are non-registrable.

**Real Case:** *Section 4(b), Designs Act 2000*.  
**Citation:** Statutory.  
**Principle:** Purely functional designs (with no aesthetic element) cannot be registered. Designs identical to earlier designs or insignificantly different are refused.  
**Source:** Indian Kanoon (indiankanoon.org/doc/854491/)

---

### Designs Rules 2001 — Infringement Remedies (Section 22)

**Proposition:** Upon infringement of a registered design, the proprietor may seek damages, accounts of profits, and injunctions in a civil suit.

**Real Case:** *The Designs Rules, 2001*, Rule 22.  
**Citation:** Statutory.  
**Principle:** Design infringement is proven by showing that the infringing article appeals to the eye in substantially the same manner as the registered design.  
**Source:** Indian Kanoon (indiankanoon.org/doc/1643916/)

---

## PCT and International Filing

### Patent Cooperation Treaty (PCT) — Procedures

**Proposition:** The PCT enables applicants to file a single international patent application that has the same effect as national applications filed in designated countries.

**Real Case:** *Patent Rules 2003*, Rule 13-14, 125-128.  
**Citation:** Statutory rules for PCT.  
**Principle:** Indian residents must file a national application in India before filing a PCT application (unless no secrecy directions are issued). The international filing date is the date of receipt by the Indian Patent Office. India is both a receiving office and a designated office under the PCT.  
**Source:** Indian Kanoon (indiankanoon.org/doc/124352296/)

---

### International Search Report (ISR) and International Preliminary Examination Report (IPER)

**Proposition:** An ISR is issued by an International Searching Authority identifying prior art against the claimed invention. An IPER is issued by an International Preliminary Examining Authority, providing preliminary non-binding comments on patentability.

**Real Case:** *Patent Rules 2003*, Rule 125-128.  
**Citation:** Statutory.  
**Principle:** Applicants may provide response statements after ISR and amend claims after IPER. In India, these documents are considered during national phase examination but are not binding on the Controller.  
**Source:** Indian Kanoon

---

### National Phase Entry — Section 139A

**Proposition:** An applicant of an international application must enter the national phase in India by filing a Form 1 (or equivalent), undertaking, and any necessary translations within 31 months of the priority date (or 30 months of international filing date, whichever is later).

**Real Case:** *Patents Act, 1970*, Section 139A; *Patents Rules 2003*, Rule 131.  
**Citation:** Statutory.  
**Principle:** Failure to file the national phase documents within this period results in abandonment of the application in India. The Controller grants the patent or issues examination reports based on national phase documents, not the ISR or IPER.  
**Source:** Indian Kanoon

---

## TRIPS, Paris Convention, Budapest Treaty

### Paris Convention — Priority Rights

**Proposition:** An applicant claiming priority in India under the Paris Convention must file a priority claim within one year of the first application filed in another Paris Convention country.

**Real Case:** *Patents Act, 1970*, Section 3(1); *Patents Rules 2003*, Rule 5(1).  
**Citation:** Statutory.  
**Principle:** Priority dates protect against intervening disclosures. India is a party to the Paris Convention (1883, as revised). A priority claim must include a certified copy of the earlier application.  
**Source:** Indian Kanoon

---

### TRIPS Agreement — Compliance

**Proposition:** The Indian Patents Act was amended to comply with TRIPS (TRIPs compliance in 2005). India now provides patent protection for methods of manufacture but maintains restrictions (e.g., Section 3(d) on pharmaceutical forms).

**Real Case:** *Novartis AG v. Union of India*, Supreme Court, 1 April 2013.  
**Citation:** 2013 (4) SCC 641.  
**Principle:** The Supreme Court upheld Section 3(d) as consistent with TRIPS Article 27 (countries may exclude certain categories), distinguishing TRIPS's "no discrimination" requirement from equality before the law. India's approach reflects the flexibilities under TRIPS Paragraph 1 of Article 27.  
**Source:** Indian Kanoon (indiankanoon.org/doc/165776436/)

---

### Budapest Treaty — Deposit of Microorganisms

**Proposition:** When a patent specification requires deposit of a microorganism, the applicant must deposit with an International Depositary Authority recognized under the Budapest Treaty (e.g., NCCS, India).

**Real Case:** *Patents Rules 2003*, Rule 5(3).  
**Citation:** Statutory.  
**Principle:** Access to the deposited material is available only after the patent's priority date, ensuring reproducibility while protecting the applicant's interests.  
**Source:** Indian Kanoon

---

## IP Jurisprudence (NEW from 2025 syllabus)

### Natural Justice in Patent Prosecution

**Proposition:** The Controller must observe principles of natural justice, including the right to hearing and reasoned orders. The Controller must specifically address each argument raised by the applicant.

**Real Case:** *Natco Pharma Limited v. Assistant Controller of Patents & Designs*, IPAB, 12 January 2023.  
**Citation:** [2023] IPAB judgment.  
**Principle:** If the Controller rejects an application, the reasons must specifically address the applicant's claims and prior art cited by the applicant. Generic or conclusory orders violate natural justice.  
**Source:** Indian Kanoon (indiankanoon.org/doc/27694029/)

---

### Doctrine of Equivalents in Infringement

**Proposition:** In patent infringement cases, courts may find infringement even if the accused product does not literally meet all elements of the claim, if it performs substantially the same function in substantially the same way to achieve substantially the same result (the "pith and marrow" test).

**Real Case:** *Bristol-Myers Squibb Company v. J.D. Joshi & Anr.*, Delhi High Court, 29 June 2015.  
**Citation:** [2015] Delhi HC judgment.  
**Principle:** The "doctrine of equivalents" has been applied in Indian infringement cases to prevent designers from circumventing patents through minor modifications. However, this doctrine must not be applied so broadly as to render claim language meaningless.  
**Source:** Indian Kanoon (indiankanoon.org/doc/29177380/)

---

### Estoppel and Prosecution History

**Proposition:** During patent prosecution, statements made by the applicant or amendments to claims may be used to interpret claim scope in infringement disputes (the doctrine of prosecution history estoppel).

**Real Case:** *Cipla Ltd. v. F. Hoffmann-La Roche Ltd.*, Delhi High Court, 27 November 2015.  
**Citation:** [2015] Delhi HC 6191.  
**Principle:** If an applicant narrows claims to overcome an objection, they may be estopped from later arguing that the claim covers subject matter expressly excluded during prosecution.  
**Source:** Indian Kanoon

---

### Public Policy and Ordre Public

**Proposition:** Patents may be denied or revoked on grounds of public policy or morality (e.g., medical devices designed for unlawful purposes) under Section 3(b) of the Patents Act.

**Real Case:** *Patents Act 1970*, Section 3(b).  
**Citation:** Statutory.  
**Principle:** While rare in application, the Controller may reject inventions offensive to public policy. Examples include methods of torture or production of weapons of mass destruction.  
**Source:** Indian Kanoon

---

## Procedural Timelines & Key Dates

- **FER issuance:** Ordinarily within 1 month, but not exceeding 2 months from reference date.
- **Response to FER:** Applicant has 12 months from FER date to respond.
- **Publication:** Application published 18 months after priority date (unless applicant requests early publication).
- **Post-grant opposition:** Must be filed within 1 year of patent grant.
- **Section 64 revocation:** May be filed anytime after patent grant (no time limit).
- **PCT priority:** 12 months from first filing date.
- **National phase entry:** 31 months from priority date (or 30 months from international filing date, whichever is later).

---

**Sources Used:**
- Indian Kanoon (indiankanoon.org) — free-access legal database
- Patents Act 1970 (India)
- Patents Rules 2003 (India)
- Designs Act 2000 (India)
- Designs Rules 2001 (India)
- Landmark cases cited above (all publicly available on IndianKanoon)